


**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Franciscan Health - Lafayette East Nuclear Medicine Dept.</p> <p>2. 1701 S. Creasy Ln. Lafayette, IN 47905</p>		<p>In accordance with letter dated November 18, 2020,</p>	<p>4. Expiration Date: November 30, 2023</p>
		<p>3. License No.: 13-09788-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-01642 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.500</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (Du Pont Merck Pharmaceutical Co., Model NES-8412; Isotope Products Laboratories, Model A3410; North American Scientific, Inc., Model MED 3601)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1 curie total</p> <p>D. 0.3 curies per source and 2 curies total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p> <p>D. For diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered in accordance with 10 CFR 30.32(g).</p>



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 13-09788-01

Docket or Reference No.:  
030-01642

Amendment No. 72

- |   |   |   |   |
|---|---|---|---|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>E. Strontium-90</p> | <p>7. Chemical and/or physical form</p> <p>E. Sealed Sources (Atlantic Research Corporation, Model B-1)</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>E. 120 millicuries total</p> | <p>9. Authorized use</p> <p>E. For storage only incident to disposal.</p> |
|---|---|---|---|



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 13-09788-01

Docket or Reference No.:  
030-01642

Amendment No. 72

CONDITIONS

10. A. Licensed material listed in Subitem Nos. 6.A. through 6.E. may be used and stored at the licensee's facilities located at 1701 S. Creasy Ln., Lafayette, Indiana.
- B. Licensed material listed in Subitem Nos. 6.A. and 6.B. may be used and stored at the licensee's facilities located at 1104 E. Grace St., Rensselaer, Indiana and 1710 Lafayette Rd., Crawfordsville, Indiana.
11. The Radiation Safety Officer (RSO) for this license is Maksym S. Dymek, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)

Material and Use

Richard L. Dobben, M.D.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Maksym S. Dymek, M.D.

10 CFR 35.100,10 CFR 35.200

John G. Felker, M.D.

10 CFR 35.100,10 CFR 35.200

Peter J. Georgis, M.D.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

Sam Hansen, M.D.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.500

Jay L. Korach, M.D.

10 CFR 35.100,10 CFR 35.200

Garry Malnar, D.O.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Robert Mehl, M.D.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to the oral administration of sodium iodide I-131),10 CFR 35.500

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 13-09788-01

Docket or Reference No.:  
030-01642

Amendment No. 72

Authorized User (M.D., D.O., etc.)

James M. Pearce, M.D.

Dennis W. Prohaska, D.O.

Michael S. Skulski, M.D.

Adel Yaacoub, M.D.

Material and Use

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.200, 10 CFR 35.500




**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 13-09788-01

Docket or Reference No.:  
030-01642

Amendment No. 72

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated June 25, 2013 (ML13296A111)
  - B. Letter dated September 30, 2013 (ML13273A500)
  - C. Letter dated February 26, 2015 (ML15063A576)
  - D. Letter dated March 23, 2015 (ML15082A406)
  - E. Letter dated April 11, 2016 (ML16104A231)
  - F. Letter dated June 14, 2017 (ML17170A317)
  - G. Letter dated November 2, 2017 (ML17317A806)
  - H. Letter dated January 23, 2018 (ML18022A177)
  - I. Letter dated November 18, 2020 (ML20325A155)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: December 14, 2020By: \_\_\_\_\_  
Magdalena R. Gryglak  
Region 3